



Amedisys Fourth Quarter 2022 Earnings Call
Supplemental Slides
February 16th, 2023

FORWARD-LOOKING STATEMENTS

This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events.

Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website <http://www.amedisys.com> or by contacting the Amedisys Investor Relations department at (225) 292-2031.

We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law.

www.amedisys.com

NASDAQ: AMED

We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press releases, profiles concerning our business, clinical operations and control processes and SEC filings.

OUR KEY AREAS OF FOCUS

Strategic areas of focus and progress made during Q4'22

1



Organic Growth

- **Home Health***: Total same store admissions +5%
- **Hospice**: Total same store admissions -8%, ADC -2%
- **Personal Care**: PC Network drove ~\$286K in revenue to Home Health and Hospice via care coordination
- **High Acuity Care**: Admissions +69% over prior year

2



Recruiting / Retention

- Targeting industry leading employee retention amongst all employee categories
- Q4'22 Voluntary Turnover 20.7%

3



Clinical Initiatives

- Quality: Amedisys Apr'23 preview STARS score of 4.49
- 99% of care centers at 4+ Stars based on Apr'23 preview
- 46 Amedisys care centers rated at 5 Stars in the Apr'23 preview
- Hospice quality – outperforming industry average in all hospice item set (HIS) categories

4



Capacity and Productivity

- Focusing on optimizing RN / LPN & PT / PTA staffing ratios.
 - Current LPN Ratio: 47.7% (vs. 49.0% in 4Q'21)
 - Current PTA Ratio: 53.9% (vs. 52.9% in 4Q'21)

5



M&A

- Acquired Evolution Health on 4/1/22 expanding our footprint in TX, OK and OH (15 care centers)
- Acquired 2 care centers from Assisted Care Home Health in North Carolina on 4/1/22
- Entered into 3 new High Acuity Care joint venture partnerships during 2022

6



Regulatory

2022 Reimbursement

- Final Home Health industry rule – Amedisys impact +3.2% increase
- Final Hospice industry rule – Amedisys impact +2.0% increase (effective 10/1/21)

2023 Reimbursement

- Final Hospice industry rule – Amedisys impact +3.8% increase (effective 10/1/22)
- Final Home Health industry rule – Amedisys impact flat (effective 1/1/23)

*Note: Home Health same store volume is defined as admissions plus recertifications

HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 4Q 2022⁽¹⁾



Home Health total same store admissions +5%; Hospice same store admissions -8%; EBITDA margin decline driven by our acquisitions (additional \$4M in losses over Q4'21), the return of sequestration (Q4'21 benefited by \$9M), planned wage increases and the shift in Home Health volumes from episodic to per visit payors



Adjusted Financial Results

\$ in Millions, except EPS	4Q21	4Q22	FY 2021	FY 2022
Home Health	\$ 337.3	\$ 342.6	\$ 1,353.8	\$ 1,364.8
Hospice	204.9	197.6	785.3	787.8
Personal Care	15.1	15.9	65.0	61.4
<u>High Acuity Care</u>	2.0	5.9	3.5	18.5
Total Revenue	\$ 559.3	\$ 562.0	\$ 2,207.6	\$ 2,232.5
<i>Gross Margin %</i>	44.1%	43.9%	45.1%	44.2%
Adjusted EBITDA	\$ 64.8	\$ 59.9	\$ 299.6	\$ 262.1
	11.6%	10.7%	13.6%	11.7%
Adjusted EPS	\$ 1.18	\$ 1.16	\$ 5.95	\$ 5.01
Free cash flow ⁽⁴⁾	\$ 1.2	\$ 36.2	\$ 174.3	\$ 114.5

Amedisys Consolidated

- Revenue Growth: +0.5%
- EBITDA: \$60M
- EBITDA Margin: 10.7% (ex. Contessa: 12.1%)
- EPS: \$1.16 (ex. Contessa: \$1.36)

Balance Sheet & Cash Flow

- Net debt: \$384.3M
- Net Leverage ratio: 1.5x
- Revolver availability: \$520.4M
- CFFO: \$40.9M
- Free cash flow ⁽⁴⁾: \$36.2M
- DSO: 46.1 (vs. Q4'21 of 43.2 and down 1.2 days since Q3)



Home Health

Same Store ⁽²⁾⁽³⁾:

- Total Admissions: +5%
- Total Volume: +1%

Other Statistics:

- Revenue per Episode⁽⁵⁾: \$2,989 (+1.3%)
- Visiting Clinician Cost per Visit: \$102.92 (+6.9%)
- Medicare VPE decreased 1.0 (-7.2%)



Hospice

Same Store Volume ⁽³⁾:

- Admissions: -8%
- ADC: -2%

Other Statistics:

- Revenue per Day: \$166.82 (-0.8%)
- Cost per day: \$86.99 (-3.6%)



Personal Care

Growth Metrics:

- Billable hours/quarter: -9%
- Clients served: -2%

Other Statistics:

- Revenue per hour: +17%
- Cost per hour: +17%



High Acuity Care

Growth Metrics:

- Total Admissions: 482
- Number of admitting JVs: 8

Other Statistics:

- Patient Satisfaction: 86%

1. The financial results for the three-month periods and years ended December 31, 2021 and December 31, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.

2. Same Store volume – Includes admissions and recertifications.

3. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center.

4. Free cash flow is defined as cash flow from operations less routine capital expenditures and required debt repayments.

5. Medicare sequestration suspended May 1, 2020; reinstated at 2% effective July 1, 2022.

OUR REVENUE SOURCES: 4Q'22






Amedisys Consolidated Revenue



Home Health Revenue



Hospice Revenue



- **Home Health:** 347 care centers; 34 states & D.C.
- **Hospice:** 164 care centers; 31 states
- **Personal Care:** 13 care centers; 3 states
- **High Acuity Care:** 8 admitting joint ventures; 6 states; 30 referring hospitals
- **Total AMED:** 532 care centers; 37 states and D.C.

- **Medicare FFS:** Reimbursed for a 30-day period of care
- **Private Episodic:** MA and Commercial plans who reimburse us for a 30-day period of care, majority of which range from 95% - 100% of Medicare rates
- **Per Visit:** Managed care, Medicaid and private payors who reimburse us per visit performed

- Hospice Per Day Reimbursement:**
- **Routine Care:** Patient at home with symptoms controlled ~97% of the Hospice care AMED provides, in line with overall hospice industry provision of care
 - **Continuous Care:** Patient at home with uncontrolled symptoms
 - **Inpatient Care:** Patient in facility with uncontrolled symptoms
 - **Respite Care:** Patient at facility with symptoms controlled

HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – Q4 2022⁽¹⁾



HOME HEALTH

\$ in Millions	Year Ended			
	4Q21	4Q22	2021	2022
Medicare	\$ 230.1	\$ 222.8	\$ 914.5	\$ 900.6
Non-Medicare	107.2	119.8	439.3	464.2
Home Health Revenue	\$337.3	\$342.6	\$1,353.8	\$1,364.8
Gross Margin %	43.8%	43.3%	45.1%	44.5%
Pre-Corporate EBITDA ⁽²⁾	\$63.3	\$59.5	\$283.0	\$260.5
	18.8%	17.4%	20.9%	19.1%

Operating Statistics

Same Store Growth ⁽³⁾⁽⁴⁾				
Total admissions	2%	5%	6%	3%
Total volume	2%	1%	5%	0%
Medicare revenue per episode ⁽⁵⁾	\$2,951	\$2,989	\$2,959	\$3,010
Medicare recert rate	35.1%	33.1%	35.1%	33.7%
Total cost per visit	\$106.67	\$114.66	\$101.46	\$109.41



Home Health Highlights

- Revenue per Episode up 1.3% (primarily due to +3.2% rate increase partially offset by the reinstatement of sequestration at 2% (~\$5M))
- Y/Y Total CPV up \$7.99 (+7.5%, primarily due to raises, wage inflation, an increase in salaried employees and visit mix)
- Cost per episode down 2.0% (Medicare)

HOSPICE

\$ in Millions	Year Ended			
	4Q21	4Q22	2021	2022
Medicare	\$ 193.9	\$ 186.3	\$ 743.6	\$ 744.1
Non-Medicare	11.0	11.3	41.7	43.7
Hospice Revenue	\$204.9	\$197.6	\$785.3	\$787.8
Gross Margin %	46.4%	47.9%	46.9%	46.4%
Pre-Corporate EBITDA ⁽²⁾	\$41.4	\$44.4	\$171.6	\$166.3
	20.2%	22.4%	21.9%	21.1%

Operating Statistics

Admit growth - same store ⁽³⁾⁽⁴⁾	-1%	-8%	2%	-1%
ADC growth - same store ⁽³⁾⁽⁴⁾	-4%	-2%	-4%	-1%
ADC	13,237	12,878	13,271	13,091
Avg. discharge length of stay	90	94	94	91
Revenue per day (net)	\$168.24	\$166.82	\$162.12	\$164.88
Cost per day	\$90.23	\$86.99	\$86.15	\$88.32



Hospice Highlights

- Net revenue per day -0.8% (+3.8% Hospice rate update effective 10/1/2022 offset by the reinstatement of sequestration at 2% and higher revenue adjustments)
- Cost per day down \$3.24 (-3.5% primarily due to clinical optimization and reorganization initiatives, lower staffing levels and lower contractor utilization partially offset by planned wage increases and wage inflation)

1. The financial results for the three-month periods and years ended December 31, 2021 and December 31, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.
2. Pre-Corporate EBITDA does not include any corporate G&A expenses.
3. Same Store information represents the percent change in volume, admissions or ADC for the period as a percent of the volume, admissions or ADC of the prior period.
4. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center.
5. Medicare revenue per completed episode reflects the suspension of sequestration for the period May 1, 2020 – March 31, 2022 and the reinstatement of sequestration at 1% on April 1, 2022 and at 2% on July 1, 2022.


GENERAL & ADMINISTRATIVE EXPENSES – ADJUSTED ^(1,2)

Impacted by acquisitions, raises and the addition of resources to support growth



\$ in Millions	4Q21	1Q22	2Q22	3Q22	4Q22
Home Health Segment - Total	84.7	83.2	87.8	86.9	89.0
% of HH Revenue	25.1%	24.8%	25.2%	25.7%	26.0%
Hospice Segment - Total	54.0	51.3	50.8	48.6	50.8
% of HSP Revenue	26.4%	26.6%	25.6%	24.4%	25.7%
Personal Care Segment - Total	2.4	2.2	2.3	2.3	2.4
% of PC Revenue	15.7%	15.8%	15.2%	14.0%	14.9%
High Acuity Care Segment - Total	6.2	7.1	8.8	8.8	8.4
% of HAC Revenue	305.7%	256.9%	199.8%	160.7%	144.2%
Total Corporate Expenses	36.1	35.6	32.7	35.5	38.0
% of Total Revenue	6.5%	6.5%	5.8%	6.4%	6.8%
Total	183.4	179.4	182.4	182.1	188.6
% of Total Revenue	32.8%	32.9%	32.2%	32.6%	33.6%

	4Q21	1Q22	2Q22	3Q22	4Q22
Salary and Benefits	21.7	23.8	23.3	22.1	24.0
Other	10.4	10.2	6.7	12.2	11.7
Corp. G&A Subtotal	32.1	34.0	30.1	34.3	35.7
Non-cash comp	4.0	1.6	2.6	1.2	2.3
Adjusted Corporate G&A	36.1	35.6	32.7	35.5	38.0



Notes:

- **Year over year total G&A as a percentage of revenue increased 80 basis points (\$5 million); excluding Contessa (\$2 million) and home health acquisitions (\$3 million), total G&A is flat versus prior year (G&A as a % of revenue excluding Contessa and home health acquisitions = 32.4%)**
 - Planned wage increases and higher information technology fees and facilities-related costs were offset by savings associated with clinical optimization and reorganization initiatives and reductions in staffing levels
- **Total G&A increased \$8 million sequentially excluding Contessa and our home health acquisitions due to higher incentive compensation costs, lower gains on the sale of fleet vehicles and a seasonality driven increase in health insurance**

1. The financial results for the three-month periods ended December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.
2. Adjusted G&A expenses do not include depreciation and amortization.


OPERATIONAL EXCELLENCE: HOME HEALTH COST PER VISIT (CPV)-ADJUSTED

YOY Total CPV impacted by labor cost pressures and lower visits



Components	4Q'21	3Q'22	4Q'22	YoY Variance	Detail	Initiatives
Salaries	\$69.73	\$72.08	\$73.94	\$4.21	YoY increase due to visit mix, planned wage increases, wage inflation and an increase in salaried employees Sequential increase due to higher new hire pay, visit mix and one additional month of raises	Staffing mix optimization, productivity and scheduling improvement initiatives in place to help overcome salary increases
Contractors	\$4.93	\$5.21	\$5.61	\$0.68	YoY variance due to an increase in rates (utilization flat) Sequential variance due to increased utilization	Focused efforts on filling positions with full-time clinicians
Benefits	\$14.52	\$14.35	\$15.66	\$1.14	YoY and Sequential variances due to higher payroll taxes on salary increases and an increase in health insurance costs due to the seasonality of claims	Focus on cost containment and spend optimization with specific focus on high-cost claims
Transportation & Supplies	\$7.10	\$7.79	\$7.71	\$0.61	YoY variance due to higher fleet fuel costs, mileage reimbursement and rate increases for freight and certain supplies	
*Visiting Clinician CPV	\$96.28	\$99.43	\$102.92	\$6.64		
Clinical Managers	\$10.39	\$11.33	\$11.74	\$1.35	Fixed cost associated with non-visiting clinicians YoY increase driven by additional staff, planned wage increases and impact of fixed costs on lower visit volumes	Unit cost reduced as volume increases
Total CPV	\$106.67	\$110.76	\$114.66	\$7.99		

*Note: Direct comparison with industry competitors CPV calculation







DRIVING TOP LINE GROWTH

Home Health admissions growth remains strong; volume impacted by mix shift. Sequential average daily census decline due to softer admission volumes and seasonality.


Home Health Growth



Hospice Growth



Personal Care Total Hours / Quarter



INDUSTRY LEADING QUALITY SCORES




Quality of Patient Care (QPC)

Metric	Jul 22 Release	Oct 22 Release	Jan 23 Release	Apr 23 Preview
Quality of Patient Care	4.46	4.49	4.49	4.49
Entities at 4+ Stars	99%	100%	99%	99%


Patient Satisfaction (PS)

Metric	Apr 22 Release	Jul 22 Release	Oct 22 Release	Jan 23 Release
Patient Satisfaction Star	3.73	3.92	3.60	3.57
Performance Over Industry	+3%	+5%	+3%	+1%

QPC Industry Performance





PS Industry Performance



- Amedisys maintains a 4-Star average in the Apr 2023 HHC Preview with **99% of our providers (representing 99% of care centers) at 4+ Stars and 82% of our providers (representing 83% of care centers) at 4.5+ Stars.**
- **31 Amedisys providers (representing 46 care centers) rated at 5 Stars.**

Notes: (1) CMS did not provide QPC Star and HH-CAHPS performance releases in 2021 due to COVID-19 PHE. (2) Apr 2023 QPC Star Preview performance period = Jul 2021 – Jun 2022 (Jul 2020 - Jun 2021 for ACH). (3) Jan 2023 HH-CAHPS Preview performance period = Jul 2021 – Jun 2022 (4) QPC Star and HH-CAHPS Results for Amedisys Legacy providers only.

HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS



Notes: Included in the above analysis are only active providers.

DEBT AND LIQUIDITY METRICS

Net leverage ~1.5x

Outstanding Debt	As of: 12/31/22
Outstanding Revolver	-
Outstanding Term Loan	435.9
Promissory Notes	0.2
Finance Leases	2.3
Total Debt Outstanding	438.4
Less: Deferred Debt Issuance Costs	(3.5)
Total Debt - Balance Sheet	434.9
<hr/>	
Total Debt Outstanding	438.4
Less Cash	(54.1)
Net Debt ⁽¹⁾	384.3
Leverage Ratio (net) ⁽²⁾	1.5
<hr/>	
Credit Facility	As of: 12/31/22
Term Loan	450.0
Revolver Size	550.0
Borrowing Capacity	1,000.0
<hr/>	
Revolver Size	550.0
Outstanding Revolver	-
Letters of Credit	(29.6)
Available Revolver	520.4
<hr/>	
Plus Cash	54.1
Total Liquidity ⁽³⁾	574.5

1. Net debt defined as total debt outstanding (\$438.4M) less cash (\$54.1M).
2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA (\$262.1M).
3. Liquidity defined as the sum of cash balance and available revolving line of credit.

CASH FLOW STATEMENT HIGHLIGHTS ⁽¹⁾

Total cash flow from operations for 2022 of \$133M. Results impacted by repayment of deferred payroll taxes (\$27M) in Q4-22 and ZPIC audit repayment (\$38M).

\$ in Millions	4Q21	1Q22	2Q22	3Q22	4Q22
GAAP Net Income	34.0	31.7	29.0	25.4	31.5
Changes in working capital	(27.1)	(5.4)	13.6	(67.3)	6.9
Depreciation and amortization	9.1	8.0	6.2	5.5	5.2
Non-cash compensation	5.9	7.3	5.1	3.5	0.6
Deferred income taxes	9.9	3.2	2.8	13.0	4.3
Other	(26.6)	3.8	0.7	6.3	(7.6)
Cash flow from operations	5.2	48.6	57.4	(13.6)	40.9
Capital expenditures - routine	(0.7)	(0.9)	(1.5)	(1.5)	(1.5)
Required debt repayments	(3.3)	(3.8)	(3.2)	(3.2)	(3.2)
Free cash flow	1.2	43.9	52.7	(18.3)	36.2
Capital Deployment					
Acquisitions	(5.1)	-	(73.3)	1.4	-
Share Repurchases	(15.0)	-	(17.4)	-	-
Total	(20.1)	-	(90.7)	1.4	-

1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.

INCOME STATEMENT ADJUSTMENTS ⁽¹⁾

Q4 adjustments primarily related to clinical optimization and reorganization initiatives, COVID-19 costs, acquisition and integration costs and severance.

\$000s	Income Statement Line Item	4Q21	1Q22	2Q22	3Q22	4Q22
Revenue						
Contingency accrual	Net Service Revenue	\$ -	\$ -	\$ 8,374	\$ 931	\$ -
Cost of Service						
Clinical optimization and reorganization costs	Cost of Service, Excluding Depreciation & Amortization	-	-	195	1,154	33
COVID-19 costs	Cost of Service, Excluding Depreciation & Amortization	4,323	3,733	1,803	1,701	1,510
Integration costs	Cost of Service, Excluding Depreciation & Amortization	-	-	1,401	311	-
Fuel supplement	Cost of Service, Excluding Depreciation & Amortization	-	337	1,016	1,962	261
G&A						
Acquisition and integration costs	G&A, Salaries and benefits	419	316	1,674	1,025	378
Clinical optimization and reorganization costs	G&A, Salaries and benefits	-	-	810	1,386	(152)
COVID-19 costs	G&A, Salaries and benefits	9	24	12	-	3
Executive Board of Directors transition award	G&A, Salaries and benefits	-	3,500	-	-	-
Severance	G&A, Salaries and benefits	-	-	-	-	993
Fuel supplement	G&A, Salaries and benefits	-	-	-	218	33
Acquisition and integration costs	G&A, Other	891	1,062	3,649	2,129	1,065
Legal fees - non-routine	G&A, Other	-	51	190	-	-
COVID-19 costs	G&A, Other	131	129	72	159	104
Clinical optimization and reorganization costs	G&A, Other	-	-	59	1,290	2,399
Legal settlement	G&A, Other	-	-	(1,058)	-	-
Other Items						
Investment impairment	Investment impairment	-	-	-	3,009	-
Interest component of certain items	Interest Expense	451	-	4,652	(207)	-
Other (income) expense, net	Total Other (Expense) Income, Net	188	2,298	760	793	814
Total		\$ 6,412	\$ 11,450	\$ 23,609	\$ 15,861	\$ 7,441
EPS Impact		\$ 0.15	\$ 0.26	\$ 0.56	\$ 0.36	\$ 0.19
EBITDA Impact		\$ 5,961	\$ 11,450	\$ 18,957	\$ 16,068	\$ 7,441

1. The financial results for the three-month periods ended December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.

2023 Guidance


AMEDISYS 2023 PRELIMINARY GUIDANCE

Revenue, EBITDA and EPS guidance ranges for FY 2023

<i>(\$M except for EPS)</i>	Total AMED
Adjusted Revenue	\$2,244 - \$2,274
Adjusted EBITDA	\$230 - \$240
Adjusted EPS	\$4.13 - \$4.36

2022 – 2023 EBITDA WATERFALL





Adjusted EBITDA Waterfall (\$M)



Category	Description
Reimbursement, Net	Home Health rate update: 0%, Hospice rate update: +3.8%
Sequestration	Headwind of \$13M from 2022 to 2023
Compensation & Benefits	Impact of 2022 raises (Aug 2022) plus 4% for 2023 raises and wage inflation; Benefits increase reflects investments focused on improving medical plans and family support: higher HSA contributions, enhanced disability coverage, paid paternal bonding leave and family caregiving leave
STI / LTI	2022 payout of 10% for corporate plan vs. 100% for 2023; lower payouts in 2022 for all other incentive compensation plans based on 2022 performance
COVID Costs	No longer adding back COVID costs in 2023 - \$6M headwind into 2023
Mix Shift	Continued shift in Home Health payor mix from episodic volumes which generate higher revenue to non-episodic volumes
Revenue Growth & Margin Improvement	Home Health total volume growth +5%; Hospice average daily census growth +3%; continued improvement in clinician utilization
Other Items	Medical supply and freight cost increases, non-recurring favorable legal settlement in 2022
Clinical Optimization & Reorganization Initiatives	Savings related to clinical optimization and reorganization initiatives
Investments	Denovos, Medalogix, workforce optimization and automation

2023 Guidance Considerations

EBITDA impacted by expiration of sequestration relief, COVID-19 costs (no longer classified as an adjusting item) and higher compensation, benefits and incentive compensation costs

Amedisys Consolidated	 Home Health	 Hospice	 Personal Care
<ul style="list-style-type: none"> • Tax rate ~27% • Cash tax rate ~19% • Diluted share count ~32.9 million shares • Capital Expenditures ~\$13-\$15 million • Salary increases and wage inflation ~4% • Benefits increase (including enhancements to medical and disability plans and new family support programs) ~7% (4% pricing/claims costs, 3% growth/headcount) • Incentive compensation increase ~ \$23 million • Excludes future acquisitions, related integration costs and potential share repurchase 	<ul style="list-style-type: none"> • Total same store admission growth: ~5% • Flat pricing • Expiration of sequestration relief -\$7 million • Continued shift in payor mix from episodic to per visit -\$14 million • Clinical optimization and reorganization initiatives +\$7 million • Continued focus on Quality of Care (Stars and Acute Care Hospitalization rates) 	<ul style="list-style-type: none"> • Total same store admission growth: ~2% • +3.8% rate increase • Expiration of sequestration relief -\$6 million • Clinical optimization and reorganization initiatives +\$10 million 	<ul style="list-style-type: none"> • On February 10, 2023, entered into a definitive agreement to sell our Personal Care line of business • Divestiture expected to close during Q2-2023 <div data-bbox="1400 625 1875 1088" style="background-color: #f0e68c; padding: 5px;"> <p data-bbox="1400 625 1506 721">  </p> <p data-bbox="1506 625 1875 721" style="text-align: center;">High Acuity Care</p> <ul data-bbox="1506 721 1875 1088" style="list-style-type: none"> • High Acuity Revenue: \$27M - \$47M • Awarded BlueCross BlueShield of TN palliative care contract </div>


2023 Investments

- Total Investments in business of ~\$8M
 - Innovations & Projects (\$6M) – spend related to automation, workforce optimization and expansion of Medalogix products
 - Denovos (\$1M) – Expansion of denovo program


2023 HIGH ACUITY SEGMENT REVENUE

(\$ in millions)

2023A to 2023P Revenue Bridge



2023 Revenue Composition by Clinical Program



(1) Excludes \$6M of 2022 revenue to be reported in Home Health segment in 2023

(2) \$47M represents the high end of the \$27M - \$47M range

Environmental, Social, Governance (E.S.G.) Considerations

ENVIRONMENTAL, SOCIAL, GOVERNANCE (E.S.G.) CONSIDERATIONS

Sustainable, high-quality, patient focused, home-based care model



Environmental	Social	Governance
<ul style="list-style-type: none"> Amedisys is dedicated to the sustainability of our business and the communities in which we serve Environmental health has a strong correlation with physical health A greener fleet – newer vehicles, in circulation for a shorter time, optimize fuel usage. Sophisticated scheduling practices reduce our clinicians’ driving time and fuel usage helping to minimize our carbon footprint Virtual care centers, along with flexible working schedules and locations, have created fewer emissions 	<ul style="list-style-type: none"> Amedisys strives to create an organizational culture and climate in which every individual is valued, all team members have a sense of belonging with one another and to the organization and feel empowered to do their best work Provider of Home Health and Hospice services to frail, elderly patients in their most preferred care location – their homes Highest quality Home Health company as measured by Quality of Patient Care Star scores (4.49 Stars) The Amedisys Foundation was formed to provide support to our patients and employees. The Amedisys Foundation has two funds: the Patients’ Special Needs Fund and the Amedisys Employees 1st Fund. The Patients’ Special Needs Fund provides financial assistance to our home health, hospice, personal care and high acuity care patients during a difficult time 	<ul style="list-style-type: none"> Amedisys has a culture of compliance starting with oversight from the Board of Directors and cascading down to the care center level Our Board of Directors operates several sub-committees including: <ul style="list-style-type: none"> Quality of Care Committee Compliance & Ethics Committee Audit Committee Compensation Committee Nominating & Corporate Governance Committee Nominating and Corporate Governance Committee oversees our strategy on corporate social responsibility, including evaluating the impact of Company practices on communities and individuals, and develops and recommends to our Board of Directors for approval matters relating to the Company’s corporate social responsibility and ESG considerations